Skip to content

Study · Not a test of the peptide alone · 2003

1 result

Effect of the peripheral target on motoneuron survival, emphasising the role of a locally acting splice variant of IGF-1

Aperghis MD

University College London (University of London)1 Jan 2003

PepBankPUB-90390652
Source linkAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MGF / PEG-MGF.

  1. 01AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Efficacy outcome

    In adult rats, MGF gene transfer before facial nerve avulsion gave marked neuroprotection of facial motoneurons at 1 month after injury.

    In plain wordsIn rats with facial nerve injury, MGF gene delivery before the injury protected nerve cells one month later.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseFacial motoneuron survival after MGF gene transfer
    Study

    ratn: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    MGF gene transfer prior to nerve avulsion conferred marked neuroprotection of facial motoneurons at 1-month post injury.
    1 context sentence
    Summary · context
    Using stereological methods, it was found that facial nerve avulsion of ad libitum-fed adult rats resulted in approximately 80% loss of motoneurons.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.